Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission

Patricia M Graves, Hellen Gelband, Paul Garner, Patricia M Graves, Hellen Gelband, Paul Garner

Abstract

Background: Mosquitoes become infected with Plasmodium when they ingest gametocyte-stage parasites from an infected person's blood. Plasmodium falciparum gametocytes are sensitive to 8-aminoquinolines (8AQ), and consequently these drugs could prevent parasite transmission from infected people to mosquitoes and reduce the incidence of malaria. However, when used in this way, these drugs will not directly benefit the individual.In 2010, the World Health Organization (WHO) recommended a single dose of primaquine (PQ) at 0.75 mg/kg alongside treatment for P. falciparum malaria to reduce transmission in areas approaching malaria elimination. In 2013, the WHO revised this to 0.25 mg/kg to reduce risk of harms in people with G6PD deficiency.

Objectives: To assess the effects of PQ (or an alternative 8AQ) given alongside treatment for P. falciparum malaria on malaria transmission and on the occurrence of adverse events.

Search methods: We searched the following databases up to 5 January 2015: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library (Issue 1, 2015); MEDLINE (1966 to 5 January 2015); EMBASE (1980 to 5 January 2015); LILACS (1982 to 5 January 2015); metaRegister of Controlled Trials (mRCT); and the WHO trials search portal using 'malaria*', 'falciparum', 'primaquine', 8-aminoquinoline and eight individual 8AQ drug names as search terms. In addition, we searched conference proceedings and reference lists of included studies, and contacted researchers and organizations.

Selection criteria: Randomized controlled trials (RCTs) or quasi-RCTs in children or adults, comparing PQ (or alternative 8AQ) as a single dose or short course alongside treatment for P. falciparum malaria, with the same malaria treatment given without PQ/8AQ.

Data collection and analysis: Two review authors independently screened all abstracts, applied inclusion criteria and extracted data. We sought evidence of an impact on transmission (community incidence), infectiousness (mosquitoes infected from humans) and potential infectiousness (gametocyte measures). We calculated the area under the curve (AUC) for gametocyte density over time for comparisons for which data were available. We sought data on haematological and other adverse effects, asexual parasite clearance time and recrudescence. We stratified the analysis by artemisinin and non-artemisinin treatments; and by PQ dose (low < 0.4 mg/kg; medium ≥ 0.4 to < 0.6 mg/kg; high ≥ 0.6 mg/kg). We used the GRADE approach to assess evidence quality.

Main results: We included 17 RCTs and one quasi-RCT. Eight trials tested for G6PD status: six then excluded participants with G6PD deficiency, one included only those with G6PD deficiency, and one included all irrespective of status. The remaining 10 trials either did not report on whether they tested (eight trials), or reported that they did not test (two trials).Nine trials included study arms with artemisinin-based treatments and eleven included study arms with non-artemisinin-based treatments.Only one trial evaluated PQ given as a single dose of less than 0.4 mg/kg. PQ with artemisinin-based treatments: No trials evaluated effects on malaria transmission directly (incidence, prevalence or entomological inoculation rate) and none evaluated infectiousness to mosquitoes. For potential infectiousness, the proportion of people with detectable gametocytaemia on day eight was reduced by around two-thirds with the high dose PQ category (RR 0.29, 95% confidence interval (CI) 0.22 to 0.37; seven trials, 1380 participants, high quality evidence) and the medium dose PQ category (RR 0.30, 95% CI 0.16 to 0.56; one trial, 219 participants, moderate quality evidence). For the low dose category, the effect size was smaller and the 95% CIs include the possibility of no effect (dose: 0.1 mg/kg: RR 0.67, 95% CI 0.44 to 1.02; one trial, 223 participants, low quality evidence). Reductions in log(10)AUC estimates for gametocytaemia on days 1 to 43 with medium and high doses ranged from 24.3% to 87.5%. For haemolysis, one trial reported percent change in mean haemoglobin against baseline and did not detect a difference between the two arms (very low quality evidence). PQ with non-artemisinin treatments: No trials assessed effects on malaria transmission directly. Two small trials from the same laboratory in China evaluated infectiousness to mosquitoes, and reported that infectivity was eliminated on day 8 in 15/15 patients receiving high dose PQ compared to 1/15 in the control group (low quality evidence). For potential infectiousness, the proportion of people with detectable gametocytaemia on day 8 was reduced by three-fifths with high dose PQ category (RR 0.39, 95% CI 0.25 to 0.62; four trials, 186 participants, high quality evidence), and by around two-fifths with medium dose category (RR 0.60, 95% CI 0.49 to 0.75; one trial, 216 participants, high quality evidence), with no trial in the low dose PQ category reporting this outcome. Reduction in log(10)AUC for gametocytaemia days 1 to 43 were 24.3% and 27.1% for two arms in one trial giving medium dose PQ. No trials systematically sought evidence of haemolysis.Two trials evaluated the 8AQ bulaquine, and suggest the effects may be greater than PQ, but the small number of participants (N = 112) preclude a definite conclusion.

Authors' conclusions: In individual patients, PQ added to malaria treatments reduces gametocyte prevalence, but this is based on trials using doses of more than 0.4 mg/kg. Whether this translates into preventing people transmitting malaria to mosquitoes has rarely been tested in controlled trials, but there appeared to be a strong reduction in infectiousness in the two small studies that evaluated this. No included trials evaluated whether this policy has an impact on community malaria transmission.For the currently recommended low dose regimen, there is currently little direct evidence to be confident that the effect of reduction in gametocyte prevalence is preserved, or that it is safe in people with G6PD deficiency.

Figures

Figure 1
Figure 1
Review logic framework: The potential points in the Plasmodium parasite life cycle that could be impacted by PQ and the outcomes used to measure impact.
Figure 2
Figure 2
Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
Figure 3
Figure 3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.
Figure 4
Figure 4
Study flow diagram.
Analysis 1.1.
Analysis 1.1.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants with gametocytes.
Analysis 1.2.
Analysis 1.2.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Gametocyte clearance time (days).
Analysis 1.3.
Analysis 1.3.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants infectious.
Analysis 1.4.
Analysis 1.4.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Mosquitoes infected.
Analysis 1.5.
Analysis 1.5.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Participants with asexual parasites at day 29.
Analysis 1.6.
Analysis 1.6.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Asexual parasite clearance time (hrs).
Analysis 1.7.
Analysis 1.7.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Adverse effects.
Analysis 1.8.
Analysis 1.8.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose: Participants with gametocytes at day 8 (microscopy).
Analysis 1.9.
Analysis 1.9.
Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By schedule: Participants with gametocytes at day 8.
Analysis 2.1.
Analysis 2.1.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants with gametocytes (microscopy).
Analysis 2.2.
Analysis 2.2.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (PCR).
Analysis 2.3.
Analysis 2.3.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants with asexual parasites.
Analysis 2.4.
Analysis 2.4.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Asexual parasite clearance time (hrs).
Analysis 2.5.
Analysis 2.5.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Haemoglobin concentration.
Analysis 2.6.
Analysis 2.6.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 6 % change in haemoglobin concentration.
Analysis 2.7.
Analysis 2.7.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Other adverse effects.
Analysis 2.8.
Analysis 2.8.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose: Participants with gametocytes at day 8 (microscopy or PCR).
Analysis 2.9.
Analysis 2.9.
Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By schedule: Participants with gametocytes at day 8 (microscopy or PCR).
Analysis 3.1.
Analysis 3.1.
Comparison 3 PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-artemisinin versus artemisinin regimen, Outcome 1 Participants with gametocytes at day 8 (microscopy or PCR).
Analysis 4.1.
Analysis 4.1.
Comparison 4 PQ versus other 8AQ, Outcome 1 Participants with gametocytes on day 8.

References

    1. Arango EA, Upegui UA, Carmona-Fonseca J. Efficacy of different primaquine-based antimalarial regimens againstPlasmodium falciparum gametocytemia. Acta Tropica. 2012;122((2012)):177–82.
    1. Chen PQ, Li GQ, Guo XB, Fu YX, He KR, Fu LC, et al. A double blind study on the infectivity of gametocytes of P. falciparum in patients treated with mefloquine and Fansimef. Journal of Guangzhou College of Traditional Chinese Medicine. 1993;10((1)):1–5.
    1. Chen PQ, Li GQ, Guo XB. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal. 1994;74((4)):209-10, 253-4.
    1. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chinese Medical Journal. 1994;107((9)):709–11.
    1. El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, et al. A randomized open-label trial of artesunate-sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS ONE. 2007;2((12)):e1311.
    1. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infectious Diseases. 2013;14((2)):130–9.
    1. Eziefula AC, Staedke SG, Yeung S, Webb E, Kamya M, White NJ, et al. Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open. 2013;3((3)):e002759.
    1. Gogtay NJ, Kamtekar KD, Dalvi SS, Chogle AR, Aigal U, Kshirsagar N. Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology. 2004;98((5)):525–8.
    1. Gogtay NJ, Kamtekar KD, Dalvi SS, Mehta SS, Chogle AR, Aigal U, et al. A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587] BMC Infectious Diseases. 2006;6:16.
    1. Kamtekar KD, Gogtay NJ, Dalvi SS, Karnad DR, Chogle AR, Aigal U, et al. A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. Annals of Tropical Medicine and Parasitology. 2004;98((5)):453–8.
    1. Khoo KK. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Annals of Tropical Medicine and Parasitology. 1981;75((6)):591–5.
    1. Kolaczinski K, Leslie T, Ali I, Durrani N, Lee S, Barends M, et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One. 2012;7((1)):e28957.
    1. Lederman ER, Maguire JD, Sumawinata IW, Chand K, Elyazar I, Estiana L, et al. Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia. Malaria Journal. 2006;5:108.
    1. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrobial Agents and Chemotherapy. 2004;48((4)):1329–34.
    1. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal. 2010;9:136.
    1. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, et al. Primaquine clears submicroscopicPlasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS ONE. 2007;2((10)):e1023.
    1. Singhasivanon V, Chongsuphajaisiddhi T, Sabchareon A, Attanath P, Webster HK, Edstein MD, et al. Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. European Journal of Drug Metabolism and Pharmacokinetics. 1994;19((1)):27–32.
    1. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases. 2010;10((10)):673–81.
    1. Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South Sumatra, Western Indonesia: an open-label, randomized, controlled trial. Clinical Infectious Diseases. 2013;56((5)):685–93.
    1. Vásquez AM, Sanín F, Alvarez LG, Tobón A, Ríos A, Blair S. Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development. Biomedica. 2009;29((2)):307–19. [Estudio piloto de la eficacia y de los efectos sobre los gametocitos del esquema artesunato-mefloquina-primaquina para la malaria por Plasmodium falciparum]
    1. Wang YS, Brown PP. Clinical study on artemether combined with Primaquine for Pf cases treatment. Tianjin Medical Journal. 2006;34((8)):538. [Chinese]
References to studies excluded from this review
    1. Baird JK, Wiady I, Sutanihardja A, Suradi, Purnomo, Basri H, et al. Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. 2002;66(6):659–60. American Journal of Tropical Medicine and Hygiene.
    1. Barber MA, Komp WHW, Newman BM. The effect of small doses of plasmochin on the viability of gametocytes of malaria as measured by mosquito infection experiments. Public Health Reports. 1929;44((24)):1409–20.
    1. Barber MA, Rice JB, Brown JY. Malaria studies on the Firestone Rubber Plantation in Liberia, West Africa. American Journal of Hygiene. 1932;15((3)):601–33.
    1. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. American Journal of Tropical Medicine & Hygiene. 1998;58((5)):645–9.
    1. Bunnag D, Harinasuta T, Pinichpongse D, Suntharasamai P. Effect of primaquine on gametocytes of Plasmodium falciparum in Thailand. Lancet. 1980;2((8185)):91.
    1. Burgess RW, Bray RS. The effect of a single dose of primaquine upon the gametocytes, gametogony and sporogony of Laverania (=Plasmodium) falciparum. 1960. pp. 1–10. World Health Organization WHO/MAL/271.
    1. Burgess RW, Bray RS. The effect of a single dose of primaquine upon the gametocytes, gametogony and sporogony of Laverania falciparum. Bulletin of the World Health Organization. 1961;24:451–6.
    1. Cai X, Yang X, He X, Zhan W, Zhan X, Ye B. The combined use of artemether, SP & PQ in the treatment of CQ-resistant Pf. Chinese Journal of Parasitology and Parasitic Diseases. 1985;3((2)):81–4. [Chinese]
    1. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malaria Journal. 2011;10:241.
    1. Che LG, Huang KG, Yang HL, Yu L, Lin ZL, Huang R. Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (Chinese Journal of Parasitology and Parasitic Diseases) 1987;5((3)):194–6.
    1. Che L, Huang K, Dong Y, Yang H, Yang P. Efficacy of two combined therapies for treatment of chloroquine-resistant P. falciparum. Chinese Journal of Parasitic Disease Control. 1990;3((1)):24–6. [Chinese]
    1. Chevalley S, Coste A, Lopez A, Pipy B, Valentin A. Flow cytometry for the evaluation of anti-plasmodial activity of drugs on Plasmodium falciparum gametocytes. Malaria Journal. 2010;9:49.
    1. Clyde DF. Mass administration of an antimalarial drug containing 4-aminoquinoline and 8-aminoquinoline in Tanganyika. Bulletin of the World Health Organization. 1962;27:203–12.
    1. Clyde DF, DuPont HL, Miller RM, McCarthy VC. Prophylactic and sporontocidal treatment of chloroquine resistant Plasmodium falciparum from Malaya. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1970;64((6)):834–8.
    1. Clyde DF, Miller RM, Music SI, McCarthy VC. Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam. American Journal of Tropical Medicine and Hygiene. 1971;20((1)):1–5.
    1. da Silva AR, Carneiro EW, dos Santos HJ. Response of human Plasmodium to antimalarials on the island of Saint Louis, State of Maranhão, Brazil. Revista do Instituto de Medecina Tropical de São Paulo. 1984;26((3)):139–46.
    1. Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bulletin of the World Health Organization. 1966;35((2)):165–79.
    1. Doi H, Kaneko A, Panjaitan W, Ishii A. Chemotherapeutic malaria control operation by single dose of Fansidar plus primaquine in North Sumatra, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health. 1989;20((3)):341–9.
    1. Giao PT, de Vries PJ, Hung le Q, Binh TQ, Nam NV, Kager PA. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Tropical Medicine and International Health. 2004;9((2)):209–16.
    1. Gogtay NJ, Chogle AR, Sorabjee JS, Marathe SN, Kshirsagar NA. Poor gametocytocidal activity of 45 mg primaquine in chloroquine-treated patients with acute, uncomplicated, Plasmodium falciparum malaria in Mumbai (Bombay): an issue of public-health importance. Annals of Tropical Medicine and Parasitology. 1999;93((8)):813–6.
    1. Gunders AE. The effect of a single dose of pyrimethamine and primaquine in combination upon gametocytes and sporogony of Laverania falciparum; Plasmodium falciparum in Liberia. Bulletin of the World Health Organization. 1961;24:650–3.
    1. Hii JL, Vun YS, Chin KF, Chua R, Tambakau S, Binisol ES, et al. The influence of permethrin-impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia. Medical and Veterinary Entomology. 1987;1((4)):397–407.
    1. Huang ZS, Fu SG, Cai XZh. Combined use of pyronaridine/SP with primaquine for P. falciparum treatment. Journal of Hainan Medicine. 1993;4((1)):10–2. [Chinese]
    1. Huang Z, Meng F, Fu S. Comparative studies on the treatment of drug-resistant P. falciparum with pyronaridine/SP and primaquine. Chinese Journal Parasitology and Parasitic Disease. 1996;14((4)):314–7. [Chinese]
    1. Huang JR, Gao YQ, Elie N. A study of artemether combined with primaquine in the treatment of falciparum malaria. Chinese Journal of Parasitology and Parasitic Diseases. 2001;19((5)):308–9. [Chinese]
    1. Jeffery GM, Young MD, Eyles DE. The treatment of Plasmodium falciparum infection with chloroquine, with a note on infectivity to mosquitoes of primaquine- and pyrimethamine- treated cases. American Journal of Hygiene. 1956;64((1)):1–11.
    1. Jeffery GM, Collins WE, Skinner JC. Antimalarial drug trials on a multiresistant strain of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene. 1963;12:844–50.
    1. Jerace F, Giovannola A. The sterilizing action of plasmochina on gametocytes of malaria parasites and its prophylactic importance. Rivista di Malariaologia. 1933;12:475. [L'azzione sterilizzante della plasmochina sui gametociti di parassiti malarigeni e sua importanza profilattica]
    1. Kaneko A, Kamei K, Suzuki T, Ishii A, Siagian R, Panjaitan W. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health. 1989;20((3)):351–9.
    1. Karbwang J, Molunto P, Bunnag D, Harinasuta T. Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. Southeast Asian Journal of Tropical Medicine and Public Health. 1991;22((1)):72–6.
    1. Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag D. Pharmacokinetics of mefloquine in the presence of primaquine. European Journal of Clinical Pharmacology. 1992;42((5)):559–60.
    1. Myat-Phone-Kyaw, Myint-Oo, Aung-Naing, Aye-Lwin-Htwe The use of primaquine in malaria infected patients with red cell glucose phosphate (G6PD) deficiency in Myanmar. Southeast Asian Journal of Tropical Medicine and Public Health. 1994;25((4)):170–13.
    1. Li J, Xiao H, Wang W, Ma W, Rao B. Artemether combined with primaquine for P.falciparum cases treatment. Clinical Medical Journal of China. 2007;14((5)):736–7. [Chinese]
    1. Li WJ, Li XL. Observation of curative effect of falciparum malaria treatment with artemether/lumefantrine and primaquine. Journal of Modern Preventive Medicine. 2010;37((5)):973–5. [Chinese]
    1. Lin L, Wang D-L, Liu B, Hu G. Artemether combined with primaquine for treatment of malaria cases from UN peace force. Chinese Journal of Parasitic Disease Control. 2004;17((5)):5–6. [Chinese]
    1. Mackerras MJ, Ercole QN. Observations on the action of quinine, atebrine and plasmoquine on the gametocytes of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1949;42((5)):455–63.
    1. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD. Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bulletin of the World Health Organization. 1968;38((4)):625–32.
    1. Rieckmann KH, McNamara JV, Kass L, Powell RD. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Military Medicine. 1969;134((10)):802–19.
    1. Santana MS, da Rocha MA, Arcanjo AR, Sardinha JF, Alecrim WD, Alecrim Md. Association of methemoglobinemia and glucose-6-phosphate dehydrogenase deficiency in malaria patients treated with primaquine. Revista da Sociedade de Brasileira de Medicina Tropical. 2007;40((5)):533–6. [Associação de metemoglobinemia e deficiência de glicose-6-fosfato desidrogenase em pacientes com malária tratados com primaquina]
    1. Shah NK, Schapira A, Juliano JJ, Srivastava B, MacDonald PD, Poole C, et al. Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. Antimicrobial Agents and Chemotherapy. 2013;57((7)):2948–54.
    1. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, vanden Bijllaardt W, vanden Bosch S, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrobial Agents and Chemotherapy. 2010;54((5)):1762–8.
    1. Skekalaghe SA, Drakeley C, vanden Bosch S, ter Braak R, vanden Bijllhaardt W, Mwanziva C, et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal. 2011;10:247.
    1. Sun W-H, Traore A. Artesunate combined with primaquine in treatment study on delay or relapse of malaria. Chinese Journal of Clinical Pharmacology and Therapeutics. 2011;1:98–100. [Chinese]
    1. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim K, Chanthapakajee K, et al. The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. American Journal of Tropical Medicine and Hygiene. 2003;68((5)):620–3.
    1. Tangpukdee N, Krudsood S, Srivilairit S, Phophak N, Chonsawat P, Yanpanich W, et al. Gametocyte clearance in uncomplicated and severe Plasmodium falciparum malaria after artesunate-mefloquine treatment in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. 2008;46((2)):65–70.
    1. Yang H, Che L, Huang K, Yang P, Dong Y, Lin Z, et al. The effect of combinations of pyronaridine, sufadoxine and primaquine on chloroquine-resistant P. falciparum. Chinese Journal of Parasitic Disease Control. 1989;2((1)):7–10.
    1. Yeramian P, Meshnick SR, Krudsood S, Chalermrut, K, Silachamroon U, Tangpukdee N, et al. Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. Journal of Infectious Diseases. 2005;192((2)):319–22.
    1. Young MD. The effect of small doses of primaquine upon malaria infections. Indian Journal of Malariology. 1959;13:69–74.
References to studies awaiting assessment
    1. Chen L. Efficacy of artemether/primaquine against drug resistant P. falciparum. Journal of Applied Medicine. 1993;1((1)):31–3. [Chinese]
    1. Ishii A, Ohta N, Owhashi M, Kawabata M, Chung D, Bobogare A, et al. Trials of transmission blocking of P. falciparum with single dose primaquine in villages of Solomon Islands. MIM conference October 2009 MIM 16723361.
    1. Li J, et al. Artemether combined with primaquine for treatment of 50 Pf cases. Journal of Applied Medicine. 2006;22((19)):2299–300. [Chinese]
References to ongoing studies
    1. Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia. Ongoing study August 2013; December 2014 (final data collection date for primary outcome measure)
    1. Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia. Ongoing study September 2014 (final data collection date for primary outcome measure)
    1. Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (MTC Belu)Sub-title: Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial. Ongoing study June 2013.
    1. Active Surveillance for P. falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia. Ongoing study December 2012; December 2014 (final data collection date for primary outcome measure)
    1. The Optimal Timing of Primaquine to Prevent Malaria Transmission After Artemisinin-Combination Therapy. Ongoing study May 2013; October 2013 (final data collection date for primary outcome measure)
    1. Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects. Ongoing study February 2012.
    1. Low Dose Primaquine for Clearance of Gametocytes: LOPRIM-1. Ongoing study September 2013.
Additional references
    1. Abay SM. Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis. Parasites and Vectors. 2013;6((1)):278.
    1. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain) Journal of Laboratory and Clinical Medicine. 1955;46((3)):391–7.
    1. Barnes, Ki, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. Journal of Infectious Diseases. 2008;197((11)):1605–13.
    1. Bhasin VK, Trager W. Chapter XI: Gametocytocidal effects in vitro of primaquine and related compounds on Plasmodium falciparum. In: Wernsdorfer WH, Trigg PI, editors. Primaquine: pharmacokinetics, metabolism, toxicity and activity. UNDP/World Bank/WHO; 1984.
    1. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal. 2010;9:136.
    1. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eradication. Clinical Microbiology Reviews. 2011;24((2)):377–410.
    1. Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One. 2012;7((8)):e42821.
    1. Breman JG. Resistance to artemisinin based combination therapy. Lancet Infectious Diseases. 2012;12((11)):820–2.
    1. Carter R, Graves PM. Gametocytes. In: Wernsdorfer, MacGregror, editors. Malaria: principles and practice of malariology. Edinburgh: Churchill Livingstone; 1988.
    1. Chotivanich K, Sattabongkot J, Udomsangpetch U, Looareesuwan S, Day NP, Coleman RE, et al. Transmission-blocking activities of quinine, primaquine, and artesunate. Antimicrobial Agents and Chemotherapy. 2006;50((6)):1927–30.
    1. Churcher TS, Bousema T, Walker M, Drakeley C, Schneider P, Ouédraogo AL, et al. Predicting mosquito infection from Plasmodium falciparum gametocye density and estimating the reservoir of infection. eLife. 2013;2:e00626.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16((1)):31–41.
    1. Drakeley, Sutherland C, Bousema JT, Sauerwein RW, Targett GA. The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends in Parasitology. 2006;22((9)):424–30.
    1. Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, Pinder M. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clinical Trials. 2006;1((4)):e20.
    1. Eichner M, Diebner HH, Molineaux L, Collins WE, Jeffery GM, Dietz K. Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malaria therapy data. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2001;95((5)):497–501.
    1. Eziefula A, Gosling R, Hwang J, Hsiang M, Bousema T, von Seidlein L, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malaria Journal. 2012;11:360.
    1. Roll Back Malaria Partnership. Global Malaria Action Plan. Geneva: RBM/WHO; 2008.
    1. Graves PM, Burkot TR, Carter R, Cattani JA, Lagog M, Parker J, et al. Measurement of malarial infectivity of human populations to mosquitoes in the Madang area, Papua New Guinea. Parasitology. 1988;96((Pt 2)):251–63.
    1. Graves PM, Burkot TR, Saul AJ, Hayes RJ, Carter R. Estimation of anopheline survival rate, vectorial capacity and mosquito infection probability from malaria infection rates in villages near Madang, Papua New Guinea. Journal of Applied Ecology. 1990;27:134–47.
    1. Higgins JPT, Altman DH, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2008. Available from .
    1. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133–201. [DOI: ]
    1. Johnston GL, Gething PW, Hay SI, Smith DL, Fidock DA. Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Computational Biology. 2014;10((1)):e1003434.
    1. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Björkman A. Malaria eradication on islands. Lancet. 2000;356((9241)):1560–4.
    1. Killeen GF, Ross A, Smith T. Infectiousness of malaria-endemic human populations to vectors. American Journal of Tropical Medicine and Hygiene. 2006;75((2 Suppl)):38–45.
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. Chichester: John Wiley & Sons; 2011.
    1. Lines JD, Wilkes TJ, Lyimo EO. Human malaria infectiousness measured by age-specific sporozoite rates in Anopheles gambiae in Tanzania. Parasitology. 1991;102((2)):167–77.
    1. Méndez F, Muñoz A, Plowe CV. Use of area under the curve to characterize transmission potential after antimalarial treatment. American Journal of Tropical Medicine and Hygiene. 2006;75((4)):640–4.
    1. Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer W. From malaria control to eradication: the WHO perspective. Tropical Medicine and International Health. 2009;14((7)):802–9.
    1. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin therapies: a pooled analysis of six randomized trials. Malaria Journal. 2008;7:125.
    1. Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Medicine. 2008;5((11)):e226.
    1. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database of Systematic Reviews. 2013;(12) [DOI: ]
    1. Price R, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, et al. The effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347((9016)):1654–8.
    1. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan) 2011. 5.1. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration.
    1. Smalley ME, Sinden RE. Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology. 1977;74((1)):1–8.
    1. Sturrock HJW, Hsiang MS, Cohen JM, Smith DL, Greenhouse B, Bousema T, et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Medicine. 2013;10((6)):e1001467.
    1. Von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends in Parasitology. 2003;19((10)):452–60.
    1. White NJ. Antimalarial pharmacokinetics and treatment regimens. British Journal of Clinical Pharmacology. 1992;34((1)):1–10.
    1. White NJ. The role of antimalarial drugs in eliminating malaria. Malaria Journal. 2008;7((Suppl 1)):S8.
    1. White NJ, Guo Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal. 2012;11:418.
    1. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infectious Diseases. 2013;13((2)):175–81.
    1. World Health Organization. Guidelines for the treatment of malaria. 2nd Edition. Geneva: WHO; 2010. Guidelines for the treatment of malaria, second edition.
    1. World Health Organization. WHO Evidence Review Group: The safety and effectiveness of single dose primaquine as a P. falciparium gametoctyocide. Meeting Report. Geneva: World Health Organization; 2012.
    1. World Health Organization. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Updated WHO Policy Recommendation. Geneva: Global Malaria Programme. World Health Organization; October 2012.
References to other published versions of this review
    1. Graves PM, Gelband H, Garner P. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database of Systematic Reviews. 2012;(9) [DOI: ]
    1. Graves PM, Gelband H, Garner P. Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission. 2014;(6) Cochrane Database of Systematic Reviews [DOI: ]

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться